These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22401627)

  • 21. Anti-CD4 cytotoxic T lymphocyte (CTL) activity in HIV+ patients: flow cytometric analysis.
    Yamamura Y; Rodriguez N; Schwartz A; Eylar E; Yano N
    Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S133-44. PubMed ID: 8574141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
    Barbour JD; Hecht FM; Wrin T; Segal MR; Ramstead CA; Liegler TJ; Busch MP; Petropoulos CJ; Hellmann NS; Kahn JO; Grant RM
    J Infect Dis; 2004 Jul; 190(2):251-6. PubMed ID: 15216458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
    Furrer H; Barloggio A; Egger M; Garweg JG;
    Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication.
    Iannello A; Boulassel MR; Samarani S; Tremblay C; Toma E; Routy JP; Ahmad A
    J Infect Dis; 2010 Feb; 201(4):608-17. PubMed ID: 20078197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network.
    Zhou P; Goldstein S; Devadas K; Tewari D; Notkins AL
    J Immunol; 1998 Feb; 160(3):1489-96. PubMed ID: 9570571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A link between immune hyperactivation of T cells during HIV-1 infection and the virus protease?
    Chiodi F
    AIDS; 2006 Mar; 20(5):769-71. PubMed ID: 16514308
    [No Abstract]   [Full Text] [Related]  

  • 27. Protease inhibitors: implications for HIV research and treatment.
    Churchill SA
    J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.
    Steyaert S; Heyndrickx L; Verhoye L; Vermoesen T; Donners H; Fransen K; Van Wanzeele F; Vandergucht B; Vanham G; Leroux-Roels G; Vanlandschoot P
    Antiviral Res; 2007 Aug; 75(2):129-38. PubMed ID: 17379323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune control of HIV-1 reservoirs.
    Autran B; Descours B; Bacchus C
    Curr Opin HIV AIDS; 2013 May; 8(3):204-10. PubMed ID: 23493099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune control of HIV-1 replication.
    Walker BD; Rosenberg ES; Hay CM; Basgoz N; Yang OO
    Adv Exp Med Biol; 1998; 452():159-67. PubMed ID: 9889969
    [No Abstract]   [Full Text] [Related]  

  • 31. Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.
    Papasavvas E; Chehimi J; Azzoni L; Pistilli M; Thiel B; Mackiewicz A; Creer S; Mounzer K; Kostman JR; Montaner LJ
    AIDS Res Hum Retroviruses; 2010 Oct; 26(10):1047-9. PubMed ID: 20718621
    [No Abstract]   [Full Text] [Related]  

  • 32. Regulation of HIV1 replication by interferon alpha: from laboratory bench to bedside.
    Gendelman HE; Baldwin T; Baca-Regen L; Swindells S; Loomis L; Skurkovich S
    Res Immunol; 1994; 145(8-9):679-84; discussion 684-5. PubMed ID: 7754219
    [No Abstract]   [Full Text] [Related]  

  • 33. [The interferon system in HIV infection].
    Kuznetsov VP
    Vopr Virusol; 1991; 36(2):92-6. PubMed ID: 1715630
    [No Abstract]   [Full Text] [Related]  

  • 34. Biology of HIV-1 in women and men.
    Burger H; Weiser B
    Clin Obstet Gynecol; 2001 Jun; 44(2):137-43. PubMed ID: 11344983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Much HIV is Alive? The Challenge of Measuring Replication Competent HIV for HIV Cure Research.
    Ananworanich J; Mellors JW
    EBioMedicine; 2015 Aug; 2(8):788-9. PubMed ID: 26425677
    [No Abstract]   [Full Text] [Related]  

  • 36. Nontransmission of HIV: a multifactorial phenomenon.
    Vernazza PL; Grunow R; Dyer JR; Pichler W
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):295-6. PubMed ID: 9117465
    [No Abstract]   [Full Text] [Related]  

  • 37. Re-examining the HIV 'functional cure' oxymoron: Time for precise terminology?
    Dubé K; Willenberg L; Dee L; Sylla L; Taylor J; Roebuck C; Palm D; Campbell D; Newton L; Patel H; Perry KE; Kanazawa J; Gerrard J; Brown B; Saberi P; Sauceda JA; Peluso MJ
    J Virus Erad; 2020 Nov; 6(4):100017. PubMed ID: 33251025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective immunity against HIV infection: has nature done the experiment for us?
    Shearer GM; Clerici M
    Immunol Today; 1996 Jan; 17(1):21-4. PubMed ID: 8652046
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel anti-HIV immunotherapy to cure HIV.
    Ahmad A; Rinaldo CR
    AIDS; 2017 Jan; 31(3):447-449. PubMed ID: 28079543
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?
    Monteverdi S; Vita E; Sartori G; Ferrara MG; D'Argento E; Tortora G; Milella M; Bria E; Pilotto S
    Transl Cancer Res; 2020 Feb; 9(2):409-414. PubMed ID: 35117384
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.